Gene Biotherapeutics, Inc. (CRXM) Stock

About Gene Biotherapeutics, Inc.

Gene Biotherapeutics, Inc. is a biotechnology company in the clinical development stage, dedicated to researching and bringing to market angiogenic gene therapy treatments for cardiovascular conditions across the United States. Its primary investigational compound, Generx, an angiogenic gene therapy candidate, is currently undergoing Phase 3 clinical trials. Generx aims to offer a potential treatment for individuals suffering from myocardial ischemia and severe, intractable angina, typically caused by advanced coronary artery disease. Furthermore, the company is exploring Generx's potential for other therapeutic applications related to ischemia affecting both the cardiovascular and cerebral systems. For the production of its Generx angiogenic gene therapy during these pivotal Phase 3 evaluations, Gene Biotherapeutics has established a manufacturing partnership with Fujifilm Diosynth Biotechnologies. Founded in 2003, the company is headquartered in San Diego, California. It officially rebranded as Gene Biotherapeutics, Inc. in January 2018, having previously operated under the name Taxus Cardium Pharmaceuticals Group, Inc.

Gene Biotherapeutics, Inc. (CRXM) stock trades at $0.00 with a market capitalization of $6493. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00.

On profitability, Gene Biotherapeutics, Inc. generates a return on equity (ROE) of 25.00% — well above the market average, a sign of a high-quality business, return on capital employed of 28.29%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: genebiotherapeutics.com